|Bid||15.41 x 1200|
|Ask||15.43 x 800|
|Day's Range||15.31 - 15.68|
|52 Week Range||10.26 - 25.88|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.17|
GERMANTOWN, Md., May 21, 2018 /PRNewswire/ -- Precigen, Inc., a wholly-owned subsidiary of Intrexon Corporation and a biopharmaceutical company specializing in the development of innovative gene and cellular therapies to improve the lives of patients, today announced the treatment of the first patient in a Phase 1 first-in-human clinical trial of its investigational therapy, INXN-4001. "This start of dosing is an exciting and important milestone for Precigen as INXN-4001 is the first investigational new drug (IND) application filed and the first patient dosed for Precigen as a newly formed wholly-owned subsidiary of Intrexon," said Helen Sabzevari, PhD, president of Precigen.
-Data from biopsies shows Ad-RTS-hIL-12 plus veledimex recruits killer T cells into breast and brain cancers. -IL-12 continues to demonstrate activity as a single-agent therapy, prolongs survival in patients ...
NEW YORK, May 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of H&R ...
GERMANTOWN, Md. , May 14, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...
NEW YORK, NY / ACCESSWIRE / May 14, 2018 / While one biotech company went up, the other went down on Friday. Intrexon shares tanked on Friday over first quarter results that didn’t impress traders, as shares of Supernus Pharmaceuticals were galloping ahead on a strong first quarter report. Intrexon Corporation shares closed down almost 20% on Friday with a little over 5 million shares traded.
Under assessment are the following four stocks: Intrexon Corp. (NYSE: XON), Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), and Jazz Pharmaceuticals PLC (NASDAQ: JAZZ). Germantown, Maryland-based Intrexon Corp.'s stock plummeted 19.64%, finishing last Friday's trading session at $14.98.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / U.S. markets eked out gains on Thursday, on the back of positive economic data and strong performance from the technology sector. The technology sector has gained ...
- Quarterly GAAP revenues of $43.8 million and net loss attributable to Intrexon of $42.0 million including non-cash charges of $26.3 million - - Adjusted EBITDA of $(19.7) million - GERMANTOWN, Md. , ...
BOSTON, May 10, 2018 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (ZIOP), today announced financial results for the first quarter ended March 31, 2018, and provided an update on the Company’s recent activities. “The landscapes of CAR-T therapies and the use of cytokines are playing out as anticipated,” said Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm. Dr. Cooper continued, “Immune-stimulatory cytokines have gained significant momentum as potential combination therapies with immune checkpoint inhibitors.
MAYNARD, Mass., May 08, 2018-- AquaBounty Technologies, Inc., a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation, ...
GERMANTOWN, Md. , May 3, 2018 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today ...
Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.
The webcast will be recorded and available for replay on the Company's website for two weeks. Ziopharm Oncology is a Boston-based biotechnology company focused on the development of next-generation immunotherapies utilizing gene- and cell-based therapies to treat patients with cancer. In partnership with Precigen Inc., a wholly-owned subsidiary of Intrexon Corporation (XON), Ziopharm is focused on the development of two platform technologies designed to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of multiple cancer types: Controlled IL-12 and Sleeping Beauty for genetically modifying T cells.
AquaBounty Technologies, Inc. (AQB) (“AquaBounty” or the “Company”), a biotechnology company focused on enhancing productivity in the aquaculture market and a majority-owned subsidiary of Intrexon Corporation (XON), today announces that it has received approval from the U.S. Food and Drug Administration (FDA) to raise AquAdvantage® Salmon at its land-based contained facility near Albany, Indiana. The FDA previously approved AquaBounty’s New Animal Drug Application (NADA) on November 19, 2015, for the production, sale, and consumption of AquAdvantage Salmon in the United States.
SIOUX CENTER, Iowa, April 16, 2018 /PRNewswire/ -- Exemplar Genetics, a wholly owned subsidiary of Intrexon Corporation (XON) committed to enabling the study of life-threatening human diseases, today announced the U.S. Food & Drug Administration (FDA) has exercised enforcement discretion in regard to the ExeGen®ATM MiniSwine model clearing it for commercial use as a research model. The ExeGen®ATM MiniSwine is genetically engineered (GE) to model ataxia telangiectasia (AT), a rare, inherited, predominantly neurological human disease. Exemplar has previously received approval for its ExeGen®LDLR MiniSwine model for use in cardiovascular disease research.
Mid-caps stocks, like Intrexon Corporation (NYSE:XON) with a market capitalization of US$2.46B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks.Read More...
NEW YORK, NY / ACCESSWIRE / April 3, 2018 / U.S. equities fell sharply on Monday, weighed down by losses in the technology sector and global trade concerns. The Dow Jones Industrial Average decreased 1.90 ...
Intrexon (XON) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GHENT, Belgium, March 29, 2018 /PRNewswire/ -- ActoBio Therapeutics, a wholly owned subsidiary of Intrexon Corporation (XON) and innovative biotechnology company focused on a new class of orally delivered biopharmaceuticals, and Intrexon T1D Partners LLC, have been granted allowance by the U.S. Food and Drug Administration (FDA) for their Investigational New Drug (IND) application to initiate a Phase Ib/IIa study for the treatment of early onset type 1 diabetes (T1D) with AG019, an innovative disease-modifying approach to induce immune tolerance in T1D. Currently no disease-modifying treatment for T1D is available, and standard of care is primarily based on exogenous insulin and diet regulation in combination with lifestyle modification.
Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Intrexon Corporation focusing on potential breaches of fiduciary duty by the Company’s Board of Directors .